Medinice S.A.

Other professional, scientific and technical activities, not elsewhere classified

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2012-12-10
Share capital
1,045,163.90 PLN
Activity description

Medinice develops advanced technologies for cardiac care, including CoolCryo, a cardiac ablation device, and PacePress. Its portfolio also includes AtriClamp for left atrial appendage occlusion, EP Bioptom for diagnostics and MiniMax, a diagnostic and therapeutic catheter. The company focuses on innovations in cardiology and cardiac surgery.

Registered address
ul. Hankiewicza 2, 02-103 Warszawa, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-81250-95237-IJVSE-17

Financials

Revenue history (in k)

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 76 days late). All were audited by a statutory auditor.

  • 202514/07/2026
  • 202414/07/2025
  • 202303/07/2024
  • 202203/07/2023
  • 202129/09/2022
  • 202008/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 45.75
-0.80 (-1.72%)
46.0047.0045.7510:0012:0014:0016:00
Open
PLN 45.90
High
PLN 47.50
Low
PLN 45.20
Volume
17K
Avg. vol.
43.97K
Market cap
PLN 424.86M
P/E ratio
–
EPS
-PLN 1.02
Shares outstanding
9.29M
52-week
PLN 43.90 – 57.60
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q3 2026USD 5.13kUSD -1.01mUSD -983.52k
Q2 2026USD 15.13kUSD -680.98kUSD -708.54k
Q1 2026USD 14.59kUSD -323.61kUSD -325.23k
Q4 2025USD 14.82kUSD -797.84kUSD -800.85k

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 56%
City · Warszawa36,070 / 56,729
Top 64%
Voivodeship · Mazowieckie50,042 / 76,892
Top 65%
Country · Poland197,607 / 297,069
Top 67%

Results vs industry

Revenue
This companyUSD 93.17kMedianUSD 55.55kAverageUSD 577.35k
Net profit
This companyUSD -1.59mMedianUSD 3.90kAverageUSD 39.36k
Operating costs
This companyUSD 1.66mMedianUSD 44.89kAverageUSD 514.16k
Assets
This companyUSD 12.90mMedianUSD 40.28kAverageUSD 835.94k

Offer

  • Medical electrotherapy devices
  • Cardiac ablation devices
  • Left atrial appendage occlusion devices
  • Diagnostic catheters
  • Diagnostic and therapeutic catheters

Websites

Trademarks

The company holds 8 active trademarks registered with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2015.

MarkNumberClassesStatusProtected until
PacePress Care (word)Z.54963610Protected Nov 25, 2032
COOLBEE (word)Z.53253810Protected Aug 10, 2031
CathAIO (word)Z.49247310Protected Nov 8, 2028
PacePress (word)Z.49246710Protected Nov 8, 2028
Mediconsole (word)Z.4924689Protected Nov 8, 2028
MarkProtected until
PacePress Care (word)Nov 25, 2032
COOLBEE (word)Aug 10, 2031
CathAIO (word)Nov 8, 2028
PacePress (word)Nov 8, 2028
Mediconsole (word)Nov 8, 2028

Authorized Representatives

Sanjeev Choudhary age 58 – President of the Management Board
Paweł Zdzisław Sobkiewicz age 53 – Attorney-in-fact (sole)

Manner of representation

If there is a one-person management board, the company is represented by 1 (one) member of the management board. If there is a multi-member management board, the company is represented by 2 (two) members of the management board acting jointly or by 1 (one) member of the management board acting jointly with a commercial proxy.

Supervisory board

Aneta Gawrońska age 50 – Supervisory Board Member
Bogdan Szymanowski age 65 – Supervisory Board Member
Joanna Bogdańska age 40 – Supervisory Board Member
Robert Dziubłowski age 63 – Supervisory Board Member
Marcin Gołębicki age 54 – Supervisory Board Member

Beneficial owners

Medinice is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Bank accounts

Registered as a VAT taxpayer on 2013-01-03.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Apr 4, 2022Commercial Companies Code notice
Nov 15, 2018Commercial Companies Code notice
Jun 11, 2018Shareholders' meeting convened
Feb 15, 2017Shareholders' meeting convened
Jan 19, 2017Shareholders' meeting convened

Public aid

14 public aid cases recorded, with a total value of $2,023,993.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
Aid for research and development projects: experimental development
–

Competitors

Name
F.R.K. Intra-Cordis sp. z o.o.
Quantum Innovations sp. z o.o.
AUG Medical sp. z o.o.
Hagmed sp. z o.o.
Spark Group sp. z o.o.
Ogarit sp. z o.o.
OPTI G sp. z o.o.
Zalimp Invest sp. z o.o.
SUMI sp. z o.o.
Biotreat Vascular sp. z o.o.

Change history

DateEvent
2026-07-23Share capital increase
2025-12-12Share capital increase
2025-06-18Share capital increase
2024-11-21Share capital increase
2023-05-25Share capital increase

FAQ

Last updated: 2026-08-28